Trials / Not Yet Recruiting
Not Yet RecruitingNCT06813664
ctDNA-Guided CURB for OPD mNSCLC on TKI (CURB-TKI)
Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Non-Small-Cell Lung Cancer on Tyrosine Kinase Inhibitor
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, prospective single arm Phase II trial that investigates the role of ablative stereotactic body radiation therapy (SBRT) in oncogene driven metastatic non-small cell lung cancer (mNSCLC) patients with oligoprogressive disease (OPD) on targeted therapy (TKI) followed by circulating tumor DNA (ctDNA) analysis for tailoring targeted therapies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Radiotherapy | SBRT/high-dose radiotherapy Standard of care targeted therapy |
| RADIATION | Radiotherapy | SBRT/high-dose radiotherapy Second-line targeted therapy |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-04-01
- Completion
- 2028-04-01
- First posted
- 2025-02-07
- Last updated
- 2026-03-04
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06813664. Inclusion in this directory is not an endorsement.